Tivantinib + Placebo + Erlotinib
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Squamous, Non-small-cell Lung Cancer
Conditions
Non Squamous, Non-small-cell Lung Cancer
Trial Timeline
Jan 11, 2011 → Dec 15, 2012
NCT ID
NCT01244191About Tivantinib + Placebo + Erlotinib
Tivantinib + Placebo + Erlotinib is a phase 3 stage product being developed by Daiichi Sankyo for Non Squamous, Non-small-cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01244191. Target conditions include Non Squamous, Non-small-cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01244191 | Phase 3 | Terminated |
Competing Products
20 competing products in Non Squamous, Non-small-cell Lung Cancer